医学
内科学
维持疗法
回顾性队列研究
队列研究
加药
比例危险模型
优势比
儿科
临床试验
前瞻性队列研究
疾病严重程度
队列
生存分析
外科
多中心研究
不利影响
疾病
年轻人
作者
Elizabeth A. Spencer,Quentin Buck,Lauren V. Collen,Ronen E. Stein,Tyler Babinski,Dror S. Shouval,Firas Rinawi,Richard Kay Russell,Eyal Zifman,Chani Topf‐Olivestone,Christos Tzvinikos,Mordechai Slae,Raffi Lev‐Tzion,Dan Turner,Marla C. Dubinsky,Amit Assa
标识
DOI:10.1093/ecco-jcc/jjag134
摘要
BACKGROUND & AIMS: Risankizumab is approved for adults with Crohn's disease (CD); pediatric data are limited. We evaluated real-world effectiveness, durability, safety, and dosing in children with CD. METHODS: Retrospective, global multicenter cohort of patients <18 years initiating risankizumab monotherapy (2022-2025). The outcomes were primary: corticosteroid-free clinical remission (CFR, wPCDAI < 12.5) post-induction (Week 12) among those with clinically active (wPCDAI ≥ 12.5) disease at start; secondary: clinical response (decrease wPCDAI ≥ 17.5-points), C-reactive protein (CRP) remission (<5 mg/L), CFR + CRP remission, intestinal ultrasound (IUS) remission, CFR at Weeks 30/54, therapy durability, and safety. RESULTS: Of the 96 (median age 15 [IQR: 13-16] years; 51% male; 70% ileocolonic; 38% prior ustekinumab) started on risankizumab, 68 (71%) had active disease at start. Nearly all (93/96, 97%) received the adult induction regimen-3 < 30 kg received a median 383 mg/m² (IQR: 339-397). Post-induction CFR was achieved in 28/68 (41%), clinical response in 37/68 (54%), and combined CFR + CRP in 22/68 (32%). Week 30 and 54 CFR were attained in 34/68 (50%) and 34/68 (50%), respectively. In the full cohort, median follow-up was 53.5 weeks (IQR: 47-60); 86/96 (90%) remained on risankizumab. Durability was greater with post-induction CFR (log-rank P = .008; Cox HR 0.21, 95% CI 0.06-0.75; P = .02). Lower baseline ESR predicted higher odds of post-induction CFR (OR 0.97 per mm/h; 95% CI 0.94-0.99; P = .01). No serious safety events occurred. CONCLUSIONS: In this multicenter pediatric cohort, risankizumab induced meaningful clinical and biomarker improvement with durable remission and a favorable safety profile, supporting risankizumab as an effective option for children with CD.
科研通智能强力驱动
Strongly Powered by AbleSci AI